MktsMarkets

Cognition Therapeutics, Inc.
NASDAQ: CGTXKey statistics
CGTX News
Stories mentioning CGTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 6,120 | 11,147 | 3,773 | 11,481 | 10,786 | 8,154 | 11,392 | 11,577 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 8,817 | 13,671 | 6,375 | 13,978 | 13,775 | 10,723 | 14,463 | 14,678 |
| Operating Income (Loss) | (8,817) | (13,671) | (6,375) | (13,978) | (13,775) | (10,723) | (14,463) | (14,678) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 4,247 | 10,328 | 1,445 | 7,244 | 5,295 | 2,881 | 4,526 | 7,637 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (4,570) | (3,343) | (4,930) | (6,734) | (8,480) | (7,842) | (9,937) | (7,041) |
| Earnings Per Share (Basic) | (0.05) | (0.05) | (0.06) | (0.11) | (0.14) | (0.20) | (0.25) | (0.18) |
| Earnings Per Share (Diluted) | (0.05) | (0.05) | (0.06) | (0.11) | (0.14) | (0.20) | (0.25) | (0.18) |
| Weighted Average Shares Outstanding (Basic) | 89,191 | 72,767 | 77,952 | 63,691 | 61,828 | 39,730 | 40,418 | 40,063 |
| Weighted Average Shares Outstanding (Diluted) | 89,191 | 72,767 | 77,952 | 63,691 | 61,828 | 39,730 | 40,418 | 40,063 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CGTX
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol CGTX. It last traded at $0.7300 (Oct 19, 2026, 1:38 PM ET), up 0.4% on the day. That gives Cognition Therapeutics a market capitalisation of $69.4M.
Over the past 52 weeks CGTX has traded between $0.5500 and $2.00.
For the quarter ended Mar 31, 2026 it reported a net loss of $4.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$4.6M |
| Dec 31, 2025 | — | -$3.3M |
| Sep 30, 2025 | — | -$4.9M |
| Jun 30, 2025 | — | -$6.7M |
From Cognition Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…